Molecular Biomarkers With Predictive Value In Metastatic Lung Cancer, Metastatic Colorectal Cancer And Unresectable And Metastatic Melanoma
Wed, 17 Feb 2021

Non-Members registration click here

Members login here and select from menu

Outlining the testing required to deliver modern day targeted therapies to metastatic cancer patients with a focus on lung, colon, and melanoma.

At the end of the session, participants will be able to:
• Facilitate the deliver of molecular results to your local oncologist.
• Discuss the relevant tests needed for treatment of NSCLC, CRC, and MM.

Target audience: Pathologists, Residents, Medical Students, Technicians

CanMEDS Roles: Medical Expert (the integrating role), Communicator, Collaborator, Health Advocate

Parneet Cheema, HBSC, MD, BIOTECH, FRCPC
Brandon Sheffield, MD, FRCPC

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.5 hour (credits are automatically calculated).

Co-Developed with Pfizer
This webinar was co-developed with Pfizer & CAP-ACP and was planned to achieve scientific integrity, objectivity and balance.

- last updated September 2020 -